The challenges multiply its coffers are emptyConclusions in line with the other work on these issues2 of the operational result current EUR 5Chrysler and Fiat have developed a partnership which has a strong chance of successHe will soon hold 30 of the voting rightsPassengers who sail to Corsica are lovers of nature68 million to various venture capital fundThere is a pole bio health but he limpingwithout that laidoff employees are compensatedA thrill that begins to resemble a renaissanceCécile Tharaud was appointed the head of Inserm Transfert for the reorganization of the activities of valorisation of Inserm, initiated in early 2006. Polytechnicienne, PhD in molecular genetics, it has, with a professional background in the industry, a double scientific approach and business.
The transfer of technology in the sector life sciences presents the specifics
It shares many characteristics with other areas of innovation, but also has its own specificities. First, research in biology more overall lies above any applications that, for example, research in electronics or computer science. This means that between an interesting scientific result and a marketable innovation, way to go, and therefore time is much longer. And this period of maturation tends to elongate. Industrial investors are now demanding that be made the "proof of concept", that is, the relevance of the technology or product has been validated with in the case of a product of the same clinical or pre-clinical data. The invention can be more quickly exploited and risks will be reduced. This maturation, essential to "sell" innovation can take 18 months to two years, during which the research team should have specific funding.
Is this the only reason for these delays
Non. At this time of scientific and technological development complements the regulatory complexity, which involves obtaining the green light from different jurisdictions and the compliance with the ethical rules. The laws of bioethics are particularly demanding in France, particularly as regards the use of stem cells or the use of gene therapy. When it comes to breaking innovations, such as cloning, researchers can be taken to suspend their work on the basis of moratorium, or the time to define the ethical frameworks. This rigor is necessary insofar as it affects the human body and its fate.
Are biologists convinced of the validity of the transfer of technology
Yes. Very many today from health products of academic research evidenced. As the dynamism of the transfer of technologies in the life sciences. Some point certainly sometimes that biologists do not have the "engineer culture" and that, for them, in any case in France, the quest for knowledge is more rewarding than development, and therefore that the publication more important than the patent. However, the same rules of evaluation researchers evolve to take into account the innovation component. INSERM Transfert, for example, currently reorganizes to facilitate the transfer of results scientific and medical of Inserm in the bed of the patient. The beneficiaries of this effort are both industrial as researchers. And course, in fine, the patients.
Are there features intellectual property
Several. Among other things, search results the more upstream of genes or target identification, are more patentable: researchers should go further downstream and identify such molecules may interact with the biological target in order to protect their invention. This assumes that the academic structures to which they belong can provide them with financial resources and access to the necessary technology platforms. The structure of technology transfer of the Medical Research Council, equivalent English of Inserm, has recently invested heavily in platforms for screening and medicinal chemistry. This evolution in the field of intellectual property is another factor which makes imperative maturation of projects.
